MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

2014年12月， 复旦大学附属肿瘤医院 在Oncotarget期刊上发表了一篇论文。在 发表4年后 ，因 图片组内重复 在pubpeer上被读者质疑。 论文题为 “Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor ...

Merck (MRK) and Eisai (ESAIY) announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, ...

Figure 5: Cell-survival pathways downstream of activated erbB receptor tyrosine kinases. The Ras–MAPK (mitogen-activated protein kinase) pathway is another important cell-proliferation pathway ...

在当今学术界，数据的准确性和研究结果的真实性是不可或缺的。这是谁都知晓的常识。然而，近日澳门科技大学的一篇论文引发了广泛关注和质疑，令人不得不思考：我们的科研是否存在隐忧？ 该论文题为"Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Facto ...

Azothbio Inc. and Daegu-Gyeongbuk Medical Innovation Foundation have described non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of autoimmune disease, ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel Pharmaceuticals KFDA greenlights Tavalisse, a ...

Unogen Biotech Ltd. has identified triple inhibitors of EGFR (HER1; erbB1), ALK tyrosine kinase receptor and hepatocyte growth factor receptor (HGFR; MET) reported to be useful for the treatment of ...

ORPATHYS ® is an oral, potent and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway ...